Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 16Brain Neoplasms 8Glioma 4Glioblastoma 4Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Diseases 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Follicular 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Breast Neoplasms 1

Interventions

Docetaxel 4enzalutamide 3darolutamide 3cabazitaxel 3Pluvicto 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2Nivolumab 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1alovudine 1abiraterone 1Standard of Care 1Single Photon Emission Computed Tomography Computed Tomography 1Selegiline 1Radium-223 1Radiosurgery 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-resistant Prostate Cancer × fluciclovine F-18 × Clear all
NCT04158245 2025-09-22

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Tulane University

Phase 2 Completed
9 enrolled 14 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡